BioStock: BioInvent’s CFO on the company’s business strategy

With a reported cash position of just over SEK 1.5 billion, BioInvent is very well-regarded compared to many life science companies of comparable size. The company’s CFO Stefan Ericsson tells BioStock what lies behind the company’s success. In particular, he highlights that the progress of the five ongoing clinical projects has increased the interest of domestic and international institutional investors.

Read the full interview with Stefan Ericsson at biostock.se:

https://www.biostock.se/en/2023/05/bioinvents-cfo-on-the-companys-business-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/